CTKB Valuation

Cytek Biosciences Inc

Add to Watchlist

Advanced Chart

3.130

-0.17(-5.152%)1D

Overview
Forecast
Valuation
Earnings

CTKB Relative Valuation

CTKB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTKB is overvalued; if below, it's undervalued.

Historical Valuation

Cytek Biosciences Inc (CTKB) is now in the Fair zone, suggesting that its current forward PE ratio of 125.20 is considered Fairly compared with the five-year average of 99.95. The fair price of Cytek Biosciences Inc (CTKB) is between 0.99 to 3.95 according to relative valuation methord.

Relative Value

Fair Zone

0.99-3.95

Current Price：3.13

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.05

P/B

Median3y

2.55

Median5y

-0.33

4.41

FCF Yield

Median3y

0.57

Median5y

0.43

Competitors Valuation Multiple

The average P/S ratio for CTKB's competitors is 2.48, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB) exhibits a P/S ratio of 1.97, which is -20.72% above the industry average. Given its robust revenue growth of -7.59%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CTKB.O

Cytek Biosciences Inc

1.97

Average P/S: 2.48

-7.59%